Form 990 for tax year 2022
Filed by FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS.
Totals
- Total revenue
- $52,477,819
- Total expenses
- $8,933,021
- Contributions and grants received
- $4,948,249
- Grants paid
- $6,744,524
- Program service revenue
- $355,507
- Investment income
- $47,780,150
- Other revenue
- -$606,087
- Total assets, end of year
- $63,075,354
- Total liabilities, end of year
- $7,259,713
- Net assets or fund balances, end of year
- $55,815,641
- Program services expenses (Part IX)
- $7,997,230
- Management and general expenses
- $579,793
- Fundraising expenses
- $355,998
- Program service expenses (Part III)
- $7,997,230
Program services were 89.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$2,787,000
-
1f · All other contributions, gifts and grants
$2,161,249
-
1g · Noncash contributions included above
$100,755
-
2a · Program service revenue: LICENSING REVENUE
total $355,507 · related or exempt $355,507
-
3 · Investment income
total $508,992 · excluded $508,992
-
7a · Gross sales of assets other than inventory
securities $15,518,426 · other assets $52,460,463
-
7b · Less cost or other basis and sales expenses
securities $14,495,550 · other assets $6,212,181
-
7c · Gain or loss
securities $1,022,876 · other assets $46,248,282
-
7d · Net gain or loss
total $47,271,158 · excluded $47,271,158
-
8a · Fundraising events: gross income
$361,783
-
8a · Fundraising events: contributions included on line 1c
$2,787,000
-
8b · Fundraising events: direct expenses
$967,870
-
8c · Net income from fundraising events
total -$606,087 · excluded -$606,087
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $6,744,524 · program services $6,744,524
-
5 · Compensation of officers, directors and key employees
total $485,109 · program services $291,906 · management and general $193,203
-
7 · Other salaries and wages
total $408,158 · program services $188,130 · management and general $105,429 · fundraising $114,599
-
10 · Payroll taxes
total $36,373 · program services $17,886 · management and general $11,990 · fundraising $6,497
-
11b · Fees: legal
total $258,494 · program services $218,635 · management and general $39,859
-
11c · Fees: accounting
total $24,665 · management and general $24,665
-
11f · Fees: investment management
total $38,460 · management and general $38,460
-
11g · Fees: other
total $31 · management and general $31
-
12 · Advertising and promotion
total $328,839 · program services $290,455 · fundraising $38,384
-
13 · Office expenses
total $11,879 · program services $7,930 · management and general $3,949
-
17 · Travel
total $119,811 · management and general $71,954 · fundraising $47,857
-
22 · Depreciation, depletion and amortization
total $14,584 · program services $14,584
-
23 · Insurance
total $2,844 · management and general $2,844
-
24a · Other expenses: EDUCATION AND AWARENESS
total $131,520 · program services $131,520
-
24b · Other expenses: VIDEO AND PRODUCTION
total $97,988 · program services $53,700 · management and general $0 · fundraising $44,288
-
24c · Other expenses: COMPUTER AND SOFTWARE E
total $75,598 · management and general $65,523 · fundraising $10,075
-
24d · Other expenses: OTHER FUNDRAISING EXPEN
total $71,339 · fundraising $71,339
-
24e · All other expenses
total $82,805 · program services $37,960 · management and general $21,886 · fundraising $22,959
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,369,488 · end of year $54,308,955
-
2 · Savings and temporary cash investments
beginning of year $7,165,247 · end of year $4,283,216
-
3 · Pledges and grants receivable
beginning of year $1,665,000 · end of year $2,316,785
-
4 · Accounts receivable
beginning of year $0 · end of year $237,629
-
10a · Land, buildings and equipment: cost or other basis
$43,753
-
10b · Land, buildings and equipment: accumulated depreciation
$29,169
-
10c · Land, buildings and equipment, net
beginning of year $29,169 · end of year $14,584
-
12 · Investments: other securities
beginning of year $6,380,671 · end of year $1,134,755
-
15 · Other assets
beginning of year $1,140,419 · end of year $779,430
-
17 · Accounts payable and accrued expenses
beginning of year $140,148 · end of year $226,506
-
18 · Grants payable
beginning of year $3,193,674 · end of year $7,033,207
-
25 · Other liabilities
beginning of year $21,070 · end of year $0
-
27 · Net assets without donor restrictions
beginning of year $14,379,645 · end of year $55,800,184
-
28 · Net assets with donor restrictions
beginning of year $15,457 · end of year $15,457
Mission and programs · 2022
Mission
ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.
Activities or mission (Part I)
THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) IS DEDICATED TO FINDING A CURE FOR ANGELMAN SYNDROME (AS) AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGGRESSIVE RESEARCH AGENDA, EDUCATION, AWARENESS, AND ADVOCACY.
-
FAST'S PRIMARY GOAL IS TO ADVANCE RESEARCH LEADING TO A CURE FOR AS IN THE FORM OF PROVIDING GRANTS TO UNIVERSITIES TO PERFORM RESEARCH AND TESTING.
Expenses $6,744,524 · Grants $6,744,524 · Revenue $355,507
-
AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE DISORDER PRESENTS. IT IS ONE OF FAST'S OBJECTIVES TO EDUCATE, SUPPORT, AND STRENGTHEN THIS COMMUNITY.
Expenses $1,252,706
As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
John SchuellterJOHN SCHUELLTER
CHAIRPERSON
- Total calculated
- $0
- Hours/week
- 30
-
Kelly DavidKELLY DAVID
CO-VICE CHAIRPERSON
- Total calculated
- $0
- Hours/week
- 30
-
Kristy DixonKRISTY DIXON
CO-VICE CHAIRPERSON AND TREASURER
- Total calculated
- $0
- Hours/week
- 25 + 2 related
-
Ben O'ConnorBEN O'CONNOR
DIRECTOR
- Total calculated
- $0
- Hours/week
- 5 + 2 related
-
Allyson BerentALLYSON BERENT
CHIEF SCIENCE OFFICER
- Total calculated
- $176,687
- From this org
- $0
- From related orgs
- $176,687
- Other
- $0
- Hours/week
- 40 + 40 related
Schedule J breakdown matched by us
- Base
- $0 + $135,913 related
- Bonus
- $0 + $40,774 related
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $0 + $176,687 related
-
Roy AzoutROY AZOUT
DIRECTOR
- Total calculated
- $0
- Hours/week
- 5
-
Ryan JacobRYAN JACOB
DIRECTOR
- Total calculated
- $0
- Hours/week
- 15 + 2 related
-
Nora XuNORA XU
DIRECTOR
- Total calculated
- $0
- Hours/week
- 5
-
Amelia BeattyAMELIA BEATTY
SECRETARY
- Total calculated
- $0
- Hours/week
- 30
-
Lauren HofferLAUREN HOFFER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 18
-
Megan CrossMEGAN CROSS
CHIEF INFORMATION OFFICER
- Total calculated
- $0
- Hours/week
- 5
-
Kena RichertKENA RICHERT
CFO
- Total calculated
- $188,000
- From this org
- $188,000
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $188,000
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $188,000
-
Alana NewhouseALANA NEWHOUSE
PRESIDENT/CEO
- Total calculated
- $50,000
- From this org
- $50,000
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
-
Paula EvansPAULA EVANS
FORMER OFFICER AND DIRECTO
- Total calculated
- $176,687
- From this org
- $0
- From related orgs
- $176,687
- Other
- $0
- Hours/week
- 0 + 40 related
Schedule J breakdown matched by us
- Base
- $0 + $135,913 related
- Bonus
- $0 + $40,774 related
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $0 + $176,687 related
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Independent compensation consultant
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 3
- THE BOARD OBTAINED A WRITTEN COMPENSATION ANALYSIS FROM WILLIS TOWERS WATSON, WHO SPECIALIZES IN EXECUTIVE COMPENSATION ASSESSMENTS. THE BOARD REVIEWED THIS COMPENSATION ANALYSIS, THE JOB DESCRIPTION, AND THE CURRENT NEEDS OF THE FOUNDATION TO SET THE COMPENSATION LEVELS FOR THE COO AND CFO POSITION.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
TEXAS A&M UNIVERSITY
$277,778
TRANSLATIONAL RESEARCH IN PIG MODEL OF AS
-
$233,299
GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A
-
NORTH CAROLINA STATE UNIVERSITY
$173,873
BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS
-
$115,121
A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA.
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 ANNUAL GALA | Total |
|---|---|---|
| Gross receipts (line 1) | $3,148,783 | $3,148,783 |
| Less contributions (line 2) | $2,787,000 | $2,787,000 |
| Gross income (line 3) | $361,783 | $361,783 |
| Cash prizes (line 4) | — | — |
| Noncash prizes (line 5) | — | — |
| Rent and facility costs (line 6) | $759,333 | $759,333 |
| Food and beverages (line 7) | — | — |
| Entertainment (line 8) | $28,000 | $28,000 |
| Other direct expenses (line 9) | $180,537 | $180,537 |
- Direct expenses (line 10)
- $967,870
- Net income (line 11)
- -$606,087
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $0
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| UNITED KINGDOM | $324,423 | — | $0 | — | — |
| ARGENTINE | $18,000 | — | $0 | — | — |
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Taxable family on this return
Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.
Related partnerships
Part III: related organizations taxable as a partnership, with the filer's share.
-
GENETX BIOTHERAPEUTICS LLC
RELATED · MEDICAL RESEARCH · DE · 58.96% owned · share of income $46,248,383 · general or managing partner
-
TRANFORMATX BIOTHERAPEUTICS LLC
RELATED · MEDICAL RESEARCH · DE · 92.63% owned · share of income -$586,331 · share of assets $494,766 · general or managing partner
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 15 November 2023
- IRS schema version
- 2022v5.0
- Source object
- 202323199349331737
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.